Skip to main content
Premium Trial:

Request an Annual Quote

Transgene Appoints Banker and Nobel Prize Winner to Board

Premium

STRASBOURG, France--Paul Berg, director of the Beckman Center for Molecular and Genetic Research at Stanford University School of Medicine, and G. Steven Burrill, CEO of Burrill & Company, a private merchant bank specializing in life sciences companies, have joined the board of directors at integrated biotech firm Transgene here.

Winner of the Nobel Prize for chemistry in 1980 for his studies of the biochemistry of nucleic acids with a specific emphasis on recombinant DNA, Berg will also participate in meetings of Transgene's scientific board.

Transgene is dedicated to the discovery and development of gene therapy technologies and products for the treatment of acquired or inherited diseases for which there is no cure or adequate therapy.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.